Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bronchioloalveolar Cancer Clear all

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma
Interventions: Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation Therapy, Carboplatin, Metformin, Paclitaxel; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 219
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
Interventions: Gefitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Interventions: OSI-774: erlotinib, TarcevaTM; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 5
States / cities: Sacramento, California • Worcester, Massachusetts • The Bronx, New York

Conditions: Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions: Double Lung Transplantation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer, Non-Small Cell
Interventions: GW572016 (lapatinib); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 23
States / cities: Jasper, Alabama • Greenbrae, California • La Jolla, California + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar
Interventions: VELCADE; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lung Cancer
Interventions: paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 85
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Lung Cancer
Interventions: bevacizumab, erlotinib hydrochloride; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 148
States / cities: Antioch, California • Berkeley, California • Burlingame, California + 109 more

Conditions: Non-small-cell Lung Cancer
Interventions: SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy); Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: pemetrexed; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 112
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Los Angeles, California + 67 more

Conditions: Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: gefitinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lung Cancer
Interventions: Ad5CMV-p53 gene; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 3
States / cities: Nashville, Tennessee • Green Bay, Wisconsin

Conditions: Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SABR); Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Interventions: Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 165
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more

Search by objective public record fields.

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer